2月26日，多家上市公司通过互动平台、披露投资者关系活动记录表等渠道披露公司在医药生物、机器 人等方面最新情况： 利亚德：公司已与国内外诸多知名机器人厂家建立合作 灿瑞科技：公司的智能传感器芯片没有应用于人形机器人 【电池】 万顺新材：高达因电池铝箔已进入小批量供应阶段 【化工】 【医药生物】 长春高新"治疗男童发育不良新药"引爆股价，公司回应：项目还处于早期阶段 博雅生物：未来将围绕基因治疗、抗体药物等领域开展研究 【机器人】 利亚德：公司机器人业务属于AI与空间计算板块，该板块营收占总营收比重约5个百分点 雅化集团：目前津巴布韦出口禁令不会对公司正常生产经营造成影响 东岳硅材：电力液体胶产品正积极对接市场 (本文来自第一财经) ...

转自：新华财经 新华财经上海2月19日电 （谷青竹）19日，上海交通大学医学院附属新华医院（以下简称"新华医院"） 传来重大科研消息：该院两项原创性研究成果登上国际顶级学术期刊《自然》（Nature），分别在罕见 病AI诊断、神经发育疾病基因治疗领域实现重大突破。 研究团队首先构建了复刻患者核心症状的人源化突变小鼠模型，为治疗研究搭建精准的"疾病模拟平 台"；并创新性设计出新型腺嘌呤碱基编辑器TeABE，与传统技术相比，全程无DNA双链断裂风险，大 幅降低基因组紊乱风险。实验显示，编辑器成功抵达突变小鼠多个脑区实现靶向修复，其社交回避、认 知迟钝、运动不协调等行为异常得到显著改善。更重要的是，团队在非人灵长类（猕猴）模型中开展实 验，也成功检测到明确的碱基编辑活性，验证了该技术的跨物种应用可行性，为后续临床试验积累了充 足前期数据。 据悉，新华医院团队深耕儿童神经发育障碍领域二十余年，致力于其遗传及环境病因的基础到临床转化 研究。李斐团队聚焦基因精准编辑，在《自然》发表重磅成果的同时，还在环境病因研究方面有所突 破，近期牵头完成的"神经发育障碍的生命早期环境风险因素识别和防控体系建立与推广"项目，在2025 ...

Group 1 - The core viewpoint of the article is that gene therapy is becoming a central focus for companies, with Hangzhou Jiayin Biotechnology Co., Ltd. officially submitting its prospectus to the Hong Kong Stock Exchange [1] - Jiayin Biotechnology, established in 2019, specializes in the development of gene therapies and oligonucleotide drugs, utilizing a dual technology platform system consisting of AAVarta and SODA [1] - The company’s research covers a wide range of diseases, including neurological disorders, ophthalmic diseases, and various hereditary and chronic conditions, resulting in a diversified product pipeline [1] Group 2 - Jiayin Biotechnology currently has 10 candidate products in development, with 4 of them already in clinical stages [2] - The core product EXG001-307, targeting SMA1 type, is set to enter Phase III clinical trials in the second half of this year and is considered the potential best-in-class candidate for SMA1 treatment in China [2] - The funds raised from the IPO will primarily be used for the further development of core products EXG001-307, key products EXG102-031 and EXG202, as well as to enhance the core technology platform and support daily operations and business expansion [2]

Core Viewpoint - CAR-T cell therapy is a revolutionary cancer treatment that utilizes genetically modified T cells to target and kill cancer cells, and it has shown promise in treating autoimmune diseases as well [2]. Group 1: Challenges of Traditional CAR-T Therapy - The preparation of CAR-T therapy is complex and expensive, involving blood extraction, genetic modification, and expansion, which can take several weeks and incur high costs [3]. - A pre-treatment with chemotherapy is required to clear the patient's existing lymphocytes before reinfusion, leading to significant side effects [3]. Group 2: Innovations in CAR-T Therapy - Researchers have proposed in vivo CAR-T cell therapy, which allows for the direct generation of CAR-T cells in the body through injection, potentially simplifying and broadening access to CAR-T therapy [4]. - A study published on February 3, 2026, introduced a novel adeno-associated virus variant, AAV6-M2, which can specifically target human T cells and generate CAR-T cells effectively in a mouse model of systemic lupus erythematosus (SLE) [4][5]. Group 3: Mechanism and Efficacy - The AAV6-M2 variant was developed using AI-assisted design and high-throughput screening, allowing it to efficiently target resting T cells without prior activation, which is crucial for in vivo CAR-T cell generation [8]. - In tests on humanized mouse models, a single injection of AAV6-M2-CD19CAR led to a 77.5% conversion rate of CD8+ T cells to CAR-T cells, effectively eliminating B cells and improving symptoms of lupus [10]. Group 4: Safety and Advantages - AAV6-M2 demonstrated significantly reduced liver tropism compared to wild-type AAV, lowering the risk of liver toxicity and enhancing the cost-effectiveness of the treatment [13]. - The study indicates that AAV-mediated CAR delivery can generate functional human CAR-T cells in vivo, marking a shift from personalized treatments to more universal, off-the-shelf products [5][14]. Group 5: Future Prospects - This research signifies a platform innovation, proving that a single systemic injection of an AAV vector can generate durable, functional human CAR-T cells, paving the way for rapid clinical translation [14]. - The application of AAV-mediated gene therapy is expanding from genetic diseases to cancer and autoimmune diseases, opening new avenues for accessible cell and gene therapies [15].

Core Viewpoint - The article discusses the revolutionary AAVLINK technology, which overcomes the limitations of adeno-associated virus (AAV) in gene therapy by enabling the delivery of large genes, thus providing new treatment possibilities for genetic diseases such as autism and epilepsy [2][27]. Group 1: AAVLINK Technology Overview - AAVLINK stands for "AAV with translocation linkage," utilizing the Cre/lox system for DNA recombination, allowing large genes to be split into smaller segments and delivered via multiple AAVs [4]. - The technology enables precise reassembly of these gene segments within cells, leading to the expression of functional proteins [4]. Group 2: Advantages of AAVLINK - AAVLINK demonstrates significant advantages over existing methods for delivering large genes, such as protein splicing and RNA splicing, which often have low efficiency and produce many by-products [6]. - In experiments, AAVLINK achieved over 25 times higher efficiency in reconstructing fluorescent proteins compared to the intein method, and up to 245 times higher in triple vector delivery [12]. - AAVLINK produces minimal by-products, ensuring safety by avoiding truncated proteins that could interfere with normal functions [12]. Group 3: Application in Disease Models - AAVLINK was tested in two disease models: Phelan-McDermid syndrome (PMS) and Dravet syndrome, successfully delivering and reconstructing the SHANK3 and SCN1A genes, respectively, leading to improved behavioral and survival outcomes in mouse models [8][11]. Group 4: CRISPR Delivery Capability - AAVLINK can also deliver large CRISPR-Cas systems, enabling gene editing and regulation, which opens new avenues for treating genetic disorders, such as lowering cholesterol levels by editing the PCSK9 gene [11]. Group 5: Safety Enhancements and Resource Availability - The development of AAVLINK 2.0 addresses potential safety risks associated with the long-term presence of Cre enzyme in the body, paving the way for clinical applications [15][17]. - AAVLINK has established a resource library containing 198 large disease-related genes and 5 CRISPR tools, allowing researchers to accelerate therapy development [19][21].

为此，研究团队创新性地提出了一种名为" AAVLINK"的新方法。该方法将长基因分成两段，分别 装进两个AAV中，一个AAV携带的基因片段装上特殊的"分子魔术贴"——lox位点，另一个AAV除了携 带另一半基因片段、lox位点外，还携带Cre重组酶基因。这两个AAV载体进入细胞后，Cre重组酶会精 准识别"魔术贴"，使拆分的两段基因精准重组，使其表达出完整的功能。另外，科研人员还开发了该技 术的2.0版本，解决了潜在的基因重排和免疫反应等生物安全问题，提升了该技术临床应用的安全性。 研究表明，该技术在多种细胞中能够高效重构大片段基因，且不产生截断蛋白，重组效率显著优于 传统方法。动物实验显示，该技术可以有效改善相关模型小鼠的行为和癫痫表型。 未来科研团队还将进一步探索该技术的全身递送效率、机制研究和疾病模型的建立，开展灵长类动 物模型的系统验证和临床前研究，推动该技术的转化落地。 记者从中国科学院深圳先进技术研究院获悉，该院科研团队历时五年，成功攻克了基因治疗领域利 用AAV（腺相关病毒载体）高效递送长基因的难题，提出了一种名为"AAVLINK"的新型基因治疗策 略，有望推动针对孤独症、癫痫等神经系统疾病和其 ...

转自：中国科学报 2020年，路中华团队联合姜玉武团队围绕这一痛点难题展开攻关。他们提出了一种名为"AAVLINK"的 新方法。该方法将长基因分成两段，分别装进两个AAV中，一个AAV携带的基因片段装上特殊的"分子 魔术贴"—lox位点，另一个AAV除了携带另一半基因片段、lox位点外，还携带Cre重组酶基因。两个装 载着基因的AAV载体进入细胞后，Cre重组酶会精准识别"魔术贴"，使拆分的两段基因精准重组，使其 表达出完整的功能。 目前，世界范围内已发现超过7000种罕见病。这类疾病大多由基因突变引发且缺乏有效治疗手段，构成 人类医学面临的重要挑战之一。近年来，基因治疗作为一种新型治疗技术，通过修复、替换或抑制致病 基因等方法，为治疗罕见病等遗传性疾病提供了新希望。 北京时间1月27日，一项发表于《细胞》的最新研究，首次提出了一种名为"AAVLINK"的新型基因治疗 策略，研究团队成功攻克了基因治疗领域利用AAV（腺相关病毒载体）高效递送长基因的难题，有望 显著推动针对孤独症、癫痫等神经系统疾病和其他遗传病的基因治疗技术的临床应用。 该研究由中国科学院深圳先进技术研究院（简称"深圳先进院"）和北京大学第一医 ...

记者从中国科学院深圳先进技术研究院获悉，该院科研团队历时五年，成功攻克了基因治疗领域利用 AAV（腺相关病毒载体）高效递送长基因的难题，提出了一种名为"AAVLINK"的新型基因治疗策略， 有望推动针对孤独症、癫痫等神经系统疾病和其他遗传病的基因治疗技术的临床应用。相关成果1月28 日在国际学术期刊《细胞》发表。 当前，世界范围内已发现超过7000种罕见病。这类疾病大多由基因突变引发且缺乏有效治疗手段，是人 类医学面临的重要挑战之一。近年来，基因治疗作为一种新型治疗技术，通过修复、替换或抑制致病基 因等方法，为治疗罕见病等遗传性疾病提供了新希望。 （文章来源：央视新闻） 为此，研究团队创新性地提出了一种名为" AAVLINK"的新方法。该方法将长基因分成两段，分别装进 两个AAV中，一个AAV携带的基因片段装上特殊的"分子魔术贴"——lox位点，另一个AAV除了携带另 一半基因片段、lox位点外，还携带Cre重组酶基因。这两个AAV载体进入细胞后，Cre重组酶会精准识 别"魔术贴"，使拆分的两段基因精准重组，使其表达出完整的功能。另外，科研人员还开发了该技术的 2.0版本，解决了潜在的基因重排和免疫反应等生物 ...

花费16万元切除肿瘤保下脾脏，还是"免费"将肿瘤和脾脏同时切除？这个选择对有一定经济能力的 人来说并不难做。 近日，第一财经记者独家了解到，有加拿大华人医生夫妇携幼女来到上海瑞金医院自费接受了一台高 难度的机器人胰腺肿瘤切除手术治疗，同时保住了女儿的脾脏，目前孩子已顺利康复出院。 他们没有选择在加拿大当地接受免费治疗的原因是被医生告知"这样的手术必须切除脾脏"。但中国医 生给出了一种两全的选项，不让患者做痛苦的"选择题"。 日前，十多位接受第一财经记者采访的专家一致认为，中国医疗远不止"性价比"，国内顶尖医疗技术 的发展水平已经不输全球发达国家，并且在一些先进技术应用方面的水平已经开始引领世界。发展国 际医疗业务对于国内医院、医生以及全球患者而言都是好事。 2026.01. 25 本文字数：5018，阅读时长大约8分钟 作者 | 第一财经 钱童心 16万保脾还是"免费"切脾？ 在加拿大温哥华执业20年的华人Kevin医生夫妇近期带着10岁的女儿来到上海交通大学医学院附属瑞 金医院胰腺外科中心求医。在成功接受了高难度的机器人胰腺手术治疗后，目前孩子已经顺利康复出 院。 Kevin在准备飞回温哥华的前一天与第一财 ...

Core Viewpoint - Wenzhou is projected to surpass a GDP of 1 trillion yuan by 2025, becoming the third city in Zhejiang province to achieve this milestone after Hangzhou and Ningbo, marking a significant completion of the "14th Five-Year Plan" [1][25]. Economic Growth - As of 2024, Wenzhou's GDP reached 971.9 billion yuan, needing less than 30 billion yuan to hit the 1 trillion yuan mark in 2025 [3][25]. - The private economy is a key driver, with 1.564 million registered private enterprises and individual businesses, accounting for 90.8% of the industrial output value of above-scale enterprises [4][26]. Industrial Development - Wenzhou plans to supply 15,200 acres of industrial land and 10,200 acres of "data-driven" land by 2025, both setting historical highs [6][28]. - The city's industrial output value increased by 10.3% year-on-year, leading the province and maintaining growth above national and provincial levels for 33 consecutive months [7][30]. Technological Innovation - High-tech industries in Wenzhou are expected to rise from 60.9% to 73% during the "14th Five-Year Plan," with a focus on the new energy sector [9][31]. - Wenzhou has established over 10 million square meters of incubator space, ranking among the top 20 cities in China for talent attraction, with industrial output exceeding 1.5 trillion yuan [9][31]. Future Development Strategy - The city aims to implement an industrial doubling plan, enhancing platforms like Wenzhou High-tech Zone and Wenzhou Economic Development Zone, targeting a manufacturing output value of 430 billion yuan [16][37]. - Wenzhou's future vision includes strengthening its role in global supply chains and enhancing trade networks, with a goal of achieving over 400 billion yuan in import and export volume [19][42]. Urban Development and Quality of Life - Wenzhou is focusing on improving living conditions and urban infrastructure, with plans to integrate 2,622 square kilometers into urban planning and attract 13,000 enterprises to its incubators [22][45]. - The city aims to enhance public services and create a family-friendly environment, with initiatives to promote education, healthcare, and community services [43][45]. Consumer Market - Wenzhou's per capita consumption level ranks among the highest in the country, with efforts to develop a regional consumption center and promote local culture and cuisine [23][46]. - The city plans to implement strategies for consumption transformation, focusing on brand aggregation and service upgrades to enhance the overall consumer experience [23][46].